Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 30/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: ClaimsFiler has alerted Ultragenyx shareholders regarding a class action lawsuit for investors who lost over $100,000. The lawsuit concerns alleged failures by the company to disclose material information during a specific period. This follows disappointing results from Phase III studies for setrusumab, which led to a significant decline in the company's stock price. Investors have until April 6, 2026, to file lead plaintiff applications in federal court.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx's Phase III studies failed to show significant results, affecting investor confidence.
  • The company's share price dropped approximately 42% following the disappointing study results.
  • Investors are reminded of the lead plaintiff deadline for a lawsuit due to material disclosures not being made.

Full Press Release Details

NEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing claims against Ultragenyx?

Investors must file lead plaintiff applications by April 6, 2026.

What triggered the lawsuit against Ultragenyx Pharmaceutical?

The lawsuit alleges Ultragenyx failed to disclose material information violating securities laws.

When did Ultragenyx report failed studies for setrusumab?

The results were announced on December 26, 2025.

How much did Ultragenyx’s share price drop after the news?

Shares fell approximately 42%, from $34.19 to $19.72.

Where can investors find more information about the lawsuit?

Visit https://claimsfiler.com/cases/nasdaq-rare/ for details.

Last updated: Feb 26, 2026